HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

Table 3 Safety summary

	Week 24		Week 48
	Abatacept + MTX (n = 40)	Adalimumab + MTX (n = 40)	Cumulative abatacept population(n = 76)
Deaths	0	1 (2.5)*	0
SAEs	1 (2.5)	2 (5.0)	4 (5.3)
Treatment-related SAEs	0	1 (2.5)^†	0
Discontinued due to SAEs	0	1 (2.5)	0
AEs	22 (55.0)	28 (70.0)	44 (57.9)
Treatment-related AEs	12 (30.0)	11 (27.5)	17 (22.4)
Discontinued due to AEs	0	1 (2.5)	0

AE adverse event, MTX methotrexate, SAE serious adverse event
Data are n (%). Week 24 database lock was used for week 24 data
SAEs include hospitalizations for elective surgical procedures. Treatment-related AE or SAE defined as AE or SAE with related or missing relationship to study medication
*Sudden death
^†Varicella infection

ISSN: 1478-6362